Navigation Links
Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
Date:5/2/2013

br>2.42$
2.72Diluted earnings per share - Non-GAAP$
8.10$
8.50Diluted weighted average common shares outstanding134.2134.2 

The reconciliation table is based in part on management's estimate of non-GAAP net income for the year ending December 31, 2013.  Actavis expects certain known GAAP charges for 2013, as presented in the schedule above.  Other GAAP charges that may be excluded from non-GAAP net income are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certainty or are presently unknown.  These GAAP charges are dependent upon future events and valuations that have not yet been performed.

The following table presents a reconciliation of forecasted net income for the twelve months ending December 31, 2013 to adjusted EBITDA:

 Table 7Actavis, Inc.Reconciliation Table - Forecasted Adjusted EBITDA(Unaudited; in millions)Forecast for Twelve MonthsEnding December 31, 2013LowHighGAAP net income

$
325$
365Plus:Interest expense

217217Interest income

(2)(2)Provision for income taxes

225255Depreciation (includes accelerated depreciation)

200200Amortization

610615EBITDA

1,5751,650Adjusted for:Global supply chain initiative

77Acquisition and licensing charges

320325Non-cash impairment charges 

(2)(2)Non-recurring (gains) losses 

(10)(10)Share-based compensation

5555Adjusted EBITDA

$
,950$
2,030 

The reconciliation table is based in part on management's estimate of adjusted EBITDA for the year ending December 31, 2013.  Actavis expects certain known GAAP charges for 2013, as presented in the schedule above.  Other GAAP charges that may be excluded from estimated EBITDA are possible, but their amounts are dependent on numerous factors that we currently cannot ascertain with sufficient certai
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
2. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
3. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
4. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
5. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
6. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
7. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
8. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
9. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
10. Watson Announces New Name -- Actavis -- for Global Operations
11. Watson and Actavis Receive FTC Second Request
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014  As power ... the country, Bernstein Liebhard LLP notes that women ... choose between a number of options that do ... surgical instrument. According to a report published by ... , these options include a mini-laparotomy and vaginal ...
(Date:8/19/2014)... 19, 2014 Research and Markets has ... of Material, by Technology, by Application & by Region- Global ... The demand for membranes is estimated to ... market to $29.31 billion Membrane technology was first ... as water filtration and kidney dialysis. In modern times, membranes ...
(Date:8/19/2014)... Avizia, Inc., a leading provider of cutting-edge ... equity financing round led by NextGen Angels along with ... will be used to continue to fuel the rapidly ... Edward Kennedy , CEO and president of Tollgrade ... Leonard Kurtzman , CFO of newBrandAnalytics, who joined the ...
Breaking Medicine Technology:As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 2As Morcellator Lawsuits Mount, Bernstein Liebhard LLP Notes Report Detailing Alternatives to Uterine Morcellation 3Global Membranes (MF, RO, UF, Gas Separation, Dialysis, NF) Market - Forecasts to 2019 2Avizia Closes Funding Round 2
... Tarsa Therapeutics today announced that the Phase III ORACAL ... treatment of postmenopausal osteoporosis was successfully concluded and yielded ... used to support a New Drug Application (NDA) submission ... the fourth quarter of 2011, based on the study ...
... YORK, March 24, 2011 Reportlinker.com announces that ... its catalogue: RNAi Drug ... http://www.reportlinker.com/p0461653/RNAi-Drug-Delivery-Technologies-and-Global-Markets.html THIS ... to how the RNAi (ribonucleic acid interference) technologies market ...
Cached Medicine Technology:Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 2Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 3Tarsa Therapeutics Reports Positive Top-Line Results From Pivotal Phase III ORACAL Trial of its Oral Calcitonin in Treatment of Postmenopausal Osteoporosis 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 2Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 3Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 4Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 5Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 6Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 7Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 8Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 9Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 10Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 11Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 12Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 13Reportlinker Adds RNAi Drug Delivery: Technologies and Global Markets 14
(Date:8/19/2014)... 19, 2014 Kars4Kids , a ... announced today its partnership with New York State Senator ... in the Bronx. The giveaway will take place in ... Crotona Park on August 22. , “With a ... believe properly preparing children for school with the necessary ...
(Date:8/19/2014)... (PRWEB) August 20, 2014 Top10BestSEOHosting.com has ... GoDaddy and iPage are the most recommended ... Joomla hosting (including VPS and cloud hosting) at an ... competitively priced products and service with some of the ... free). They give their loyal customers a lot of ...
(Date:8/19/2014)... 2014 Grande Naturals, LLC is ... of the 2014 Independent Cosmetics Manufacturers & Distributors ... place position in “Product Innovation; Product Color Cosmetic” ... also includes a lash enhancement serum, GrandeLINER™. ... technology. , This all-new eyeliner is ...
(Date:8/19/2014)... HealthDay Reporter TUESDAY, ... be added to the list of possible harms related ... treat behavioral symptoms of dementia in older adults, a ... olanzapine (Zyprexa) are approved by the U.S. Food and ... serious mental disorders. They are also frequently used "off-label" ...
(Date:8/19/2014)... York (PRWEB) August 19, 2014 As ... Bernstein Liebhard LLP notes the publication of a new ... may increase the risk of acute kidney injury in ... Ottawa Citizen, the study was conducted by researchers at ... the Institute for Clinical Evaluative Sciences, and looked at ...
Breaking Medicine News(10 mins):Health News:Backpack Giveaway Kars4Kids Partners with New York State Senator Gustavo Rivera to Prepare Bronx Students for New School Year 2Health News:Top10BestSEOHosting.com: Cheap Joomla Hosting Reviews Unveiled 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 2Health News:GrandeLINER™ Wins Independent Cosmetics Manufacturers & Distributors Award 3Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 2Health News:Certain Antipsychotic Meds Tied to Kidney Problems in Elderly 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 2Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 3Health News:As Risperdal Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Linking Atypical Antipsychotic Medications to Kidney Damage in Elderly Patients 4
... A large proteomics study on the brains of newborn ... in obstetric or pediatric medicine can have profound and ... This study, appearing in the December issue of ... of the developing nervous system and reinforces the use ...
... , , WEST ORANGE, N.J., Dec. ... birthday. This year, to her great joy, she was able to experience ... transplant that has a much shorter recovery time than a traditional transplant, ... , , Katherine, who still lives in ...
... Dr Ben Berkhout, a retrovirologist from the Netherlands, ... Retrovirology Prize. He was honoured for his ... additional important building blocks for many aspects of ... research has extended our insights into the mechanisms ...
... C. Benjamin, MD, FACP, FACEP (E), Executive Director, American Public ... Dec. 11 "At a time when national interest in ... Public Health Association (APHA) applauds President-elect Obama for prioritizing health ... Department of Health and Human Services, as well as the ...
... face infection, bleeding, study finds , , THURSDAY, Dec. 11 ... who,ve had multiple, previous pocket procedures have an increased ... a study that included the 12 largest ICD implanting ... the London Health Sciences Center in Ontario, and colleagues ...
... President and CEO of America,s Health Insurance Plans (AHIP), ... nomination of Senator Tom Daschle to be the next ... Services: , , "The ... Daschle because it signals that the incoming administration intends ...
Cached Medicine News:Health News:The profound effects of numbing agents 2Health News:Centenarian's Vision Restored With New Sutureless Corneal Transplant Technology 2Health News:Multiple ICD Replacements Can Predict Complications 2
... The Awaya stereo test was developed to ... Awaya Stereo test employs the more reliable ... eye. It is not dependent on polarizing spectacles ... first target is an attractive image of a ...
... is designed to assist patients with red-green color ... filter cuts off wavelengths shorter than 582 nm ... of their most difficult color distinctions. A color ... determine whether a color is in the longer ...
Features a twist-on backswitch, with a diffused, cobalt blue light beam....
Heavy duty, all purpose illuminator available in blue and green. Unique Clip Switch automatically turns off when returned to pocket. Pre-focused lens tip Heine XHL Halogen bulb for bright, concentra...
Medicine Products: